NASDAQ · SABS
SAB Biotherapeutics, Inc.
$3.23+$0.03 (+0.94%)
SAB Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.28% below the high.
Loading market information…
NASDAQ · NUWE · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Nuwellis, Inc.’s quoted price sits in the lower half of its reported 52-week range, 99.63% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Nuwellis, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$122.85. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Nuwellis, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Nuwellis, Inc., a medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy. The company provides Aquadex FlexFlow and Aquadex SmartFlow systems, which are used to treat patients suffering from fluid overload due to heart failure, as well as Aquadex SmartFlow system for temporary use in adult and pediatric patients. The company was formerly known as CHF Solutions, Inc. and changed its name to Nuwellis, Inc. in April 2021. Nuwellis, Inc. was founded in 1999 and is headquartered in Eden Prairie, Minnesota.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 10:49 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2025 | May 13, 2025 | -$1,014.30-615.56% vs estimate | $1.90M-23.84% vs estimate |
|---|
| Q4 2024 | Mar 11, 2025 | -$138.60-2.33% vs estimate | $2.32M-5.67% vs estimate |
|---|
| Q3 2024 | Nov 11, 2024 | $548.10+235.94% vs estimate | $2.37M+0.38% vs estimate |
|---|
THE ANALYST VIEW
2 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$3.23+$0.03 (+0.94%)
SAB Biotherapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 37.28% below the high.
$3.31-$0.19 (-5.43%)
BriaCell Therapeutics Corp.’s quoted price sits in the lower half of its reported 52-week range, 75.35% below the high.
$0.68-$0.01 (-1.31%)
PetVivo Holdings, Inc.’s quoted price sits in the lower half of its reported 52-week range, 54.67% below the high.
$1.97-$0.07 (-3.43%)
Aclarion, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.95% below the high.
$0.17+$0.17 (+100.0%)
Holdco Nuvo Group D.G Ltd. Ordinary Shares’s quoted price sits in the lower half of its reported 52-week range, 22.73% below the high.
$0.54-$0.02 (-3.6%)
INVO Fertility, Inc.’s quoted price sits in the lower half of its reported 52-week range, 97.98% below the high.
$0.02$0.00 (0.0%)
Peak Bio, Inc.: Healthcare · Biotechnology.
$0.00-$0.00 (-25.0%)
Ocean Biomedical, Inc.’s quoted price sits in the lower half of its reported 52-week range, 89.83% below the high.
